1 / 29

Risk Factors

Risk Factors. Corticosteroids Existing arthritis Articular infection Infection elsewhere DM Trauma None. Frequency of Joints. Knee Hip Ankle Elbow Wrist Shoulder Sternoclavicular. Pathology. High vascularity

leat
Download Presentation

Risk Factors

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Risk Factors • Corticosteroids • Existing arthritis • Articular infection • Infection elsewhere • DM • Trauma • None

  2. Frequency of Joints • Knee • Hip • Ankle • Elbow • Wrist • Shoulder • Sternoclavicular

  3. Pathology • High vascularity • S. aureus collagen-binding adhesin associated with osteomylitis but not septic joint • Disruption of normal joint by pre-existing joint disease • Proteolytic enzymes released

  4. Signs and Symptoms • Joint pain, swelling, warmth, and decreased range of motion • Joint tenderness to pressure or movement • Tendon tenderness • Fever • May resemble acute crystal dz. or hemothrosis

  5. Organisms Associated • Neisseria-1-12% • Non-gonorrhea-S. aureus-37-56%, Streptococcal-10-28%, GNR-4-19%, coagulase negative staph-5%, anaerobic-2%, PMB-less than 10% • Am Rheum Disease-2002, 61:267

  6. Septic Arthritis-odd organisms • Lyme, Mycoplasma • Listeria, enterococcus, chlmydia • M. tuberculosis, atypical Tb • Candida, sporothrix, blastomycosis, coccidiom\ • Rubella, hep b and c, EBV, parvovirus, mumps

  7. Synovial Effusion • Normal-clear, viscous, colorless-<200 wbc (<25% pmns) • Noninflammatory-clear, viscous, yellow 200-2000 wbc-<25% pmns • Inflammatory-cloudy, watery, yellow-2000-50,000 cells (>50% polys)

  8. Synovial Effusion, continued • Infected-purulent->50,000 cells (>75% pmns) • Great overlap at times

  9. Gonococcal vs. non gc Arthritis • Gc-sexually active adults, migratory polyarthralgias, tenosynovitis, dermatitis common, >50% polyarthritis, BC positive <10%, joint fluid positive 25%

  10. GC vs. non GC • Non GC-very young or elderly, polyarthralgias, tenosynovitis rare, dermatitis rare, >85% monoarthritis, BC positive 50%, joint fluid positive 85-90% • NEJM-1985, 312:764-771

  11. Outcome of Bacterial Arthritis • 154, 121 adults-half had joint disease • 29% of joints contained synthetic material • Poor outcome in 21% of patients • Poor joint outcome in nearly 50% of patients

  12. Outcome continued • Risk factors for poor outcome include-older age, existing joint disease, synthetic joint • Arthritis and Rheumatism • 1997, 40:884.

  13. Factors Associated with Poor Prognosis • Age >60 years • Pre-existing rheumatoid arthritis or hip or shoulder infection • >1 week of infection • >4 joints involved • Positive cultures after 7 days of appropriate treatment

  14. Management • Antimicrobials do achieve adequate levels in joint fluid • Joint effusion drainage necessary but best method to drain is uncertain

  15. Prosthetic Hip Infxns, Organisms • Gram positive-CNSE>S. aureus>streptococcus>enterocc • Gram negative-Enteric>pseudomonas • Anaerobes least common • J Bone Jt. Surg-1996, 78:512

  16. Results of Rx of Infxns-Prosthetic Hip • Positive intraoperative-28/31 good outcome (90%) 3.5 year followup • Early Postoperative 25/35 (71% good outcome) 3.3 yrs followup • Late chronic-29/34 (85%) good outcome-2.6 years followup

  17. Results of Treatment continued • Acute hematogenous-3/6 (50%) good outcome-2.6 years followup • Journal Bone and Joint Surgery 1996, 78:512

  18. Prosthetic Joint Infection • Positive intraoperative cx-6 weeks iv with no surgical Rx • Early (one month)-surgical, remove lines, leave bone components, 4 weeks iv antibiotics

  19. Prosthetic Joint Infection • Late chronic infection-debridement, remove components and cement, 6 weeks iv antibiotics • Acute hematogenous-treatment same as early postoperative, replace components if loose • J Bone Jt Surg 1995, 77: 1576

  20. Rifampin Containing Regimens • Proven S. aureus or coagulase negative staph infxns. • Stable joint with sms less than 21 days • Initial debridement and 2 weeks of antistaph followed by oral for 3 months if hip or 6 months if hip

  21. Rifampin Containing Regimens • 12/12 cured with cipro+rifampin • 7/12 cured with cipro plus placebo • JAMA-1998, 279, 1537 • Lancet 2001, 1:175.

  22. Suppression with oral • In one study of patients who were high risk/poor function if joint removed-treatment mean was 37.6 months • 10/13 patients required prothesis removal for recurrent infections (mean 21.6 months

  23. Suppression-continued • Conclusion-benefits are limited • Orthopaedics-1991, 14:841.

  24. Osteomyelitis classification • Cierny and Mader-Orthopaedic Review-1987, 16:259 • I-medullary, II-superficial, III-localized, IV-diffuse • Host factors-A-normal, B-compromised, C-prohibitive • Waldvogel-NEJM-1970, 282:198 • Hematogenous, continguous

  25. Osteomyelitis diagnosis • Staging studies-MRI, CT, nuclear scans, ESR, CRP, bone biopsies and cultures

  26. Osteomyelitis treatment • Surgery and antibiotics • Controversies in length of treatment, etc.

  27. Diabetic Foot • MRI-99% sensitive, 83% specific • Plain x-ray-60% sensitive, 66% specific • Tc99m bone scan-86% sensitive, 45% specific • In111 WBC-89% sensitive, 78% specific, CID 1997: 25: 1318

  28. Probing to Bone • Technique to determine bone infection • Sterile, steel probe used • positive test if bone can be touched with probe • Sensitivity-89%, specificity-85% JAMA-1995. 273:721

  29. Diabetic Foot • 254 isolates from 96 patients • S. aureus-38 isolates, Enterococcus-31, peptostreptococcus-31, CNSE-27, streptococcus sp-27, proteus-10, klebsiella-10 • CID-1995, 20 (supplement 2).

More Related